Potential of Febuxostat for management of hyperuricemia in gout patients

Primary tabs

Potential of Febuxostat for management of hyperuricemia in gout patients

When the excess uric acid forms crystals in joints and other tissues, this condition is known as gout arthritis. It causes painful inflammation in the joint area. To lower the uric acid levels and the frequency of gout attacks, Vitamin C, cherries and other integrative interventions have been explored.

In the last decades, febuxostat is a potential alternative to the scarce number of urate-lowering medications which are available. It is a selective inhibitor of both isoforms of xanthine oxido-reductase (XOR) as well as a non-purine. Its efficiency can be seen on comparison with allopurinol as it's inhibition of XOR is more potent than allopurinol in a mg to mg values. Thus, it is associated to achieve serum urate target more frequently than allopurinol at doses tested in clinical trials, especially in patients with the highest baseline serum urate levels. In patients with chronic kidney disease, its pharmacokinetics is not greatly dependent on renal clearance as opposite to allopurinol; hence, adding to an advantage.

In renal function preservation, many trials are still under-way for evaluating both the cardiovascular safety of febuxostat and its possible beneficial effect. In transplant patients, insufficient but clinically engaging evidence has been recently delivered.

Expert Rev Clin Pharmacol.
Therapeutic, Febuxostat, Hyperuricemia, Gout, Chronic, Cardiovascular safety.
Log in or register to post comments